Thermo Fisher Scientific and Danaher reported diverging second-quarter results, with Thermo Fisher raising its full-year guidance while Danaher lowered the upper end of its core revenue growth outlook. Thermo Fisher's revenue grew 10% to $11.99 billion, with adjusted EPS up 13% to $6.03, driven by broad-based demand improvement across pharmaceutical and biotech markets. Danaher's core growth improved sequentially but was marked by uneven recovery, including a $100 million revenue shift into next year due to customer project timing. Hedge fund ownership of Thermo Fisher rose to 115 funds in the first quarter of 2026 from 113 in the prior quarter, while Danaher's fell from 125 to 110 funds over the same period.
Thermo Fisher Scientific IncThermo Fisher raised full-year guidance with 10% revenue growth driven by broad-based demand improvement across pharma and biotech markets.
Danaher CorporationDanaher lowered upper end of core revenue growth outlook and had $100M revenue shift due to customer project timing, indicating uneven demand recovery.
